Research shows that an aqueous extract from the Erigeron annuus plant significantly reduced skin inflammation and improved barrier function in mice with atopic dermatitis-like lesions, working by calming overactive immune responses and blocking inflammatory signaling pathways. According to Gram Research analysis, the extract decreased dermatitis scores, reduced water loss through damaged skin, lowered allergic antibodies and inflammatory proteins, and decreased immune cell infiltration into skin tissue. However, these results come from animal studies, so human clinical trials are needed before this plant extract could become a treatment option for people.
Researchers tested a natural plant extract called Erigeron annuus on mice with a skin condition similar to atopic dermatitis, a common inflammatory skin disorder that causes itching and redness. According to Gram Research analysis, the extract significantly reduced skin inflammation, improved the skin’s protective barrier, and calmed down the immune system’s overactive response. The study found that the plant extract worked by blocking specific inflammatory pathways in the body. While these results are encouraging, the research was conducted in mice, so scientists need to test it in humans before recommending it as a treatment for people with atopic dermatitis.
Key Statistics
A 2026 study published in Pharmaceutical Biology found that Erigeron annuus extract significantly reduced dermatitis scores and decreased transepidermal water loss in mice with ovalbumin-induced atopic dermatitis-like skin lesions.
Research showed that the plant extract reduced serum total IgE antibodies and ovalbumin-specific IgE antibodies in treated mice compared to untreated controls, indicating suppression of allergic immune responses.
The extract decreased interleukin-4 and interleukin-13 levels in skin tissue and reduced mast cell infiltration, key markers of allergic inflammation in atopic dermatitis.
Laboratory experiments demonstrated that pyromeconic acid, a compound from the plant extract, suppressed MAPK signaling activation and inflammatory mediator expression in lipopolysaccharide-stimulated immune cells.
The Quick Take
- What they studied: Whether a natural extract from the Erigeron annuus plant could reduce skin inflammation and improve symptoms in mice with atopic dermatitis-like skin lesions.
- Who participated: Female BALB/c mice (a common laboratory mouse breed) that were 5 weeks old. Researchers created skin inflammation in these mice by repeatedly exposing them to a protein called ovalbumin, which triggered an allergic-like skin reaction similar to atopic dermatitis in humans.
- Key finding: The plant extract significantly reduced skin inflammation scores, improved skin barrier function, and decreased immune system markers associated with allergic skin reactions. Mice treated with the extract showed reduced water loss through their skin, better skin hydration, and lower levels of inflammatory proteins compared to untreated mice.
- What it means for you: This research suggests that natural plant extracts may help manage atopic dermatitis by working on multiple levels: strengthening the skin barrier, reducing allergic immune responses, and blocking inflammatory pathways. However, these results are from animal studies, so human trials are needed before this could become a treatment option.
The Research Details
Researchers used laboratory mice to model atopic dermatitis, a chronic skin condition characterized by inflammation, itching, and a weakened skin barrier. They created skin lesions in the mice by repeatedly applying a protein called ovalbumin to their skin, which triggered an allergic response similar to what happens in human atopic dermatitis. Half the mice received an oral dose of Erigeron annuus extract for six weeks, while the control group did not receive the extract.
The researchers then measured multiple outcomes to determine if the extract worked. They examined the mice’s skin under a microscope to look for signs of inflammation and damage. They also measured how much water was escaping through the skin (a sign of a damaged barrier), tested blood samples for immune markers like antibodies and inflammatory proteins, and analyzed skin tissue for specific immune cells and signaling molecules involved in inflammation.
Additionally, the researchers isolated immune cells called macrophages in a laboratory dish and tested whether a specific compound from the plant extract could reduce their inflammatory response when stimulated with a bacterial component called lipopolysaccharide.
This research approach is important because atopic dermatitis involves multiple problems at once: a damaged skin barrier, an overactive immune system, and inflammatory signaling inside cells. By testing the plant extract in a living organism (mice), researchers could see if it could address all these problems together, not just one in isolation. The combination of animal studies with laboratory cell studies helps researchers understand both whether something works and how it works, which is crucial for developing new treatments.
This study has several strengths: it used a well-established animal model of atopic dermatitis, measured multiple relevant outcomes (skin barrier function, immune markers, and inflammatory pathways), and included both in vivo (whole animal) and in vitro (laboratory cell) experiments. However, the main limitation is that results from mouse studies do not always translate to humans. Additionally, the abstract does not specify the exact sample size of mice used, which makes it harder to assess statistical power. The study was published in a peer-reviewed journal, which means other experts reviewed the methods and findings before publication.
What the Results Show
The Erigeron annuus extract significantly reduced visible signs of skin inflammation in the treated mice compared to untreated mice. Dermatitis scores, which measure the severity of skin lesions, were substantially lower in the extract-treated group. The extract improved the skin’s barrier function by decreasing transepidermal water loss (water escaping through damaged skin) and increasing skin hydration, indicating that the skin’s protective layer was restored.
Microscopic examination of skin tissue showed that the extract reduced thickening of both the outer layer of skin (epidermis) and the deeper layer (dermis), which typically occurs with inflammation. The extract also decreased the number of mast cells, immune cells that release inflammatory chemicals, infiltrating the skin tissue.
At the immune system level, the extract reduced the accumulation of immune cells called CD4+ and CD8+ T cells in the skin and prevented enlargement of the spleen, an organ that becomes swollen during allergic responses. Most importantly, the extract lowered levels of specific immune markers associated with allergic reactions: serum total IgE antibodies, ovalbumin-specific IgE antibodies, and inflammatory proteins called interleukin-4 and interleukin-13 in the skin.
The extract also reduced the activity of specific inflammatory signaling pathways inside skin cells. Researchers measured phosphorylation of extracellular signal-regulated kinase and p38, which are key molecules in the MAPK signaling pathway that controls inflammation. The extract decreased the expression of interleukin-1 beta, another inflammatory protein. In laboratory experiments with immune cells, a specific compound from the plant extract called pyromeconic acid suppressed MAPK activation and reduced the production of inflammatory mediators when cells were stimulated with bacterial components.
Erigeron annuus has been used in traditional medicine for inflammatory conditions, but this is one of the first studies to systematically examine its effects on atopic dermatitis-like skin lesions. The findings align with previous research showing that natural plant extracts can modulate immune responses and reduce inflammation through MAPK pathway inhibition. However, most prior studies on plant-based treatments for atopic dermatitis have focused on single mechanisms, whereas this study examined multiple pathways simultaneously, providing a more comprehensive picture of how the extract works.
The primary limitation is that this research was conducted in mice, not humans. Mouse models of atopic dermatitis do not perfectly replicate the human disease, so results may not translate directly to people. The study does not specify the exact number of mice used in each group, making it difficult to assess whether the sample size was adequate. The contribution of pyromeconic acid, the specific compound tested in laboratory cells, to the overall effects of the whole plant extract in living mice remains unclear. Additionally, the study did not test different doses of the extract or compare it to existing atopic dermatitis treatments, so it is unclear how effective it might be relative to current options. Finally, long-term safety and potential side effects were not evaluated.
The Bottom Line
Based on this animal study, Erigeron annuus extract appears to be a promising candidate for further research as a potential complementary treatment for atopic dermatitis. However, human clinical trials are necessary before it can be recommended for actual use. People currently managing atopic dermatitis should continue using established treatments prescribed by their healthcare provider. If interested in plant-based approaches, discuss options with a dermatologist or healthcare provider who can evaluate safety and potential interactions with current medications.
This research is most relevant to researchers studying atopic dermatitis and natural anti-inflammatory compounds, dermatologists interested in plant-derived treatments, and people with atopic dermatitis who are interested in complementary approaches. People with severe atopic dermatitis, pregnant or nursing women, and those taking medications that might interact with plant extracts should consult healthcare providers before considering any new treatment. This research should not replace conventional medical treatment at this stage.
Since this is an early-stage animal study, it will likely take several years of additional research before any potential human treatment could be available. Typically, promising animal studies are followed by laboratory safety testing, then small human pilot studies, and finally larger clinical trials. This process usually takes 5 to 10 years or longer before a new treatment reaches patients.
Frequently Asked Questions
Can I use Erigeron annuus extract to treat my atopic dermatitis right now?
Not yet. This research was conducted in mice, not humans. While results are promising, human clinical trials are needed to confirm safety and effectiveness in people before it can be recommended as a treatment. Continue using treatments prescribed by your dermatologist.
How does this plant extract help atopic dermatitis?
The extract works through multiple mechanisms: it strengthens the skin’s protective barrier by restoring a protein called filaggrin, reduces allergic immune responses by lowering antibodies and inflammatory proteins, and blocks inflammatory signaling pathways inside skin cells called MAPK pathways.
What is atopic dermatitis and why is it hard to treat?
Atopic dermatitis is a chronic inflammatory skin condition causing itching, redness, and a damaged skin barrier. It is difficult to treat because it involves multiple problems simultaneously: barrier dysfunction, overactive immune responses, and inflammatory signaling, so treatments need to address all these issues.
When will this plant extract be available as a treatment?
If development continues, it typically takes 5 to 10 years or longer from animal studies to human treatment availability. The next steps would be safety testing, small human pilot studies, and larger clinical trials before any potential approval.
Are there any risks to using plant extracts for skin conditions?
Plant extracts can cause allergic reactions, interact with medications, or have unknown side effects. Always consult your healthcare provider before using any new treatment, especially if you are pregnant, nursing, or taking other medications.
Want to Apply This Research?
- Users interested in atopic dermatitis management could track daily skin symptoms using a simple scoring system: photograph affected areas weekly, rate itching intensity on a 1-10 scale, measure affected body surface area, and note triggers that worsen symptoms. This baseline data would be valuable if they eventually discuss plant-based treatments with their healthcare provider.
- Users could implement evidence-based skin care practices while waiting for further research: establish a consistent moisturizing routine immediately after bathing, identify and avoid personal triggers (certain fabrics, soaps, or environmental factors), maintain a symptom diary to correlate with potential triggers, and schedule regular check-ins with their dermatologist to monitor disease progression.
- Create a long-term tracking system that records monthly photos of affected skin areas, weekly symptom severity ratings, medication usage, and identified environmental or dietary triggers. Share this data with healthcare providers during regular appointments to objectively assess whether current treatments are working and to inform discussions about emerging therapies as research progresses.
This article summarizes research findings from an animal study and is for educational purposes only. It does not constitute medical advice. Atopic dermatitis is a medical condition that should be managed under the supervision of a qualified healthcare provider or dermatologist. Do not start, stop, or change any treatment without consulting your healthcare provider. While the research is promising, Erigeron annuus extract is not currently approved as a medical treatment for atopic dermatitis in humans. Pregnant women, nursing mothers, and people taking medications should consult their healthcare provider before using any plant-based supplements or extracts, as they may cause allergic reactions or drug interactions. If you have atopic dermatitis, continue using treatments prescribed by your healthcare provider while staying informed about emerging research.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.